Efficacy and safety of antiplatelet therapy in COVID-19: Insights from a meta-analysis of randomized controlled trials
CONCLUSION: Antiplatelet therapy does not confer mortality benefit in COVID-19 patients but lowers major thrombotic events while increasing major bleeding risks. Ongoing large RCTs will provide more information on the therapeutic value of this therapy.PMID:38469705 | DOI:10.5414/CP204497
Source: Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Guoying Kao Yunlin Chen Jinqi Fan Source Type: research
More News: Bleeding | COVID-19 | Drugs & Pharmacology | Hypertension | Respiratory Medicine | Statistics